Medical Advocates

HCV Infection/Disease
 
Drugs
General Reports
Amantadine

Asunaprevir
Boceprevir
Cyclosporine
Etanercept
Erythropoietin
Corticosteroids

Gammaglobulin
Immunoglobulin
Interferons
Lopinavir
Meloxicam
Metformin

Nevirapine

Peg Interferon-Alfa-2a 
Peg Interferon-Alfa-2b  
Raltegravir
Ribavirin

Rifampin
Rituximab
Statins
Stribid
Tacrolimus
Telaprevir
Thalidomide
Valproic Acid
Alternative Therapies
Investigational Therapies
Post-Transplant Drugs








 

HCV Main Page Main New/Newsworthy    Home Page    

Last Update:  May 19, 2013
 
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

General Reports
 

     Journal Papers, Abstracts, and Commentaries

 
A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice.
Bruce RD, Moody DE, Altice FL,  et al
Expert Rev Clin Pharmacol
. 2013 May;6(3):249-69.
Abstract

Earlier Sustained Virologic Response Endpoints for Regulatory Approval and Dose Selection of Hepatitis C Therapies.
Chen J, Florian J, Carter W, Fleischer RD, et al
Gastroenterology
. 2013 Mar 4.
Abstract

 
A Survey of Hepatitis C Treatment Clinical Practice Patterns Using the Newly Approved Protease Inhibitors.
Chen EY, Lee WM, Hynan LS, Singal AG.
J Clin Gastroenterol
. 2013 Mar .

Abstract

A Survey of Hepatitis C Treatment Clinical Practice Patterns Using the Newly Approved Protease Inhibitors.
Chen EY, Lee WM, Hynan LS, Singal AG.
J Clin Gastroenterol
. 2013 Mar .
Abstract

Antiviral resistance and direct-acting antiviral agents for HCV.
Aloia AL, Locarnini S, Beard MR.
Antivir Ther. 2012;17(6 Pt B):1147-62.
Abstract

Future perspectives: towards interferon-free regimens for HCV.
Gane E.
Antivir Ther
. 2012;17(6 Pt B):1201-10.
Abstract

Highly active anti-hepatitis C therapy: seven lessons from HIV.
Thomas DL.
Antivir Ther
. 2012;17(6 Pt B):1183-8.
Abstract

HCV Variants with Decreased Sensitivity to Direct Acting Antivirals Were Rarely Observed in DAA-Naive Patients Prior to Treatment.
Bartels DJ, Sullivan JC, Zhang EZ, et al 
J Virol
. 2012 Nov 14.
Abstract

The changing face of hepatitis C in the new era of direct-acting antivirals.
Soriano V, Labarga P, Fernández-Montero JV,  et al
Antiviral Res
. 2012 Nov 9.
Abstract

FULL-TEXT PDF ARTICLE
New therapeutic options for HCV infection in the monoclonal antibody era.
Sautto GA, Diotti RA, Clementi M.
New Microbiol. 2012 Oct;35(4):387-97.

Abstract

Pharmacokinetics of new oral hepatitis C antiviral drugs.
Vispo E, Barreiro P, Soriano V.
Expert Opin Drug Metab Toxicol. 2012 Oct 25.
Abstract

New hepatitis C virus drug discovery strategies and model systems.
Hussain S, Barretto N, Uprichard SL.

Expert Opin Drug Discov
. 2012 Sep;7(9):849-59.
Abstract

Current and emerging antiviral treatments for hepatitis C infection.
Doyle JS, Aspinall E, Liew D, et al
Br J Clin Pharmacol. 2012 Aug 13.
Abstract

New antiviral therapies in the management of HCV infection.
Farnik H, Zeuzem S.

Antivir Ther
. 2012 May 25. 
Abstract

Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus.
Barritt AS 4th, Fried MW
Gastroenterology. 2012 May;142(6):1314-1323.
Abstract

FULL-TEXT ARTICLE
New antiviral agents for hepatitis C.
Pawlotsky JM.
F1000 Biol Rep. 2012;4:5..
Paper

Antiviral Drugs and the Treatment of Hepatitis C.
Jalali Z, Rockstroh JK.
Curr HIV/AIDS Rep. 2012 Feb 22
Abstract

Antiviral strategies in hepatitis C virus infection.
Sarrazin C, Hézode C, Zeuzem S, Pawlotsky JM.
J Hepatol. 2012;56 Suppl:S88-S100
Abstract

Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow.
Asselah T, Marcellin P.
Liver Int.2012 Feb;32 Suppl 1:88-102. .
Abstract

Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
Halfon P, Sarrazin C.
Liver Int. 2012 Feb;32 Suppl 1:79-87.
.
Abstract

New targets for antiviral therapy of chronic hepatitis C.
Bühler S, Bartenschlager R.
Liver Int. 2012 Feb;32 Suppl 1:9-16.
Abstract

FULL-TEXT ARTICLE
The therapeutic approaches for hepatitis C virus: protease inhibitors and polymerase inhibitors.
Kwo PY, Vinayek R.
Gut Liver. 2011 Dec;5(4):406-17
Paper

Provisional Guidance on the Use of Hepatitis C Virus Protease Inhibitors for Treatment of Hepatitis C
in HIV-Infected Persons.
Thomas DL, Bartlett JG, Peters MG, et al
Clin Infect Dis. 2011 Dec 14
Abstract

Recent advance in antiviral drugs for hepatitis C.
Liu J, Shi S, Zhuang H, Luo G.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2011 Nov;36(11):1025-36.
Abstract

Mechanisms Involved in the Development of Chronic Hepatitis C as Potential Targets of Antiviral Therapy.
Jackowiak P, Figlerowicz M, Kurzyńska-Kokorniak A, Figlerowicz M.
Curr Pharm Biotechnol
. 2011 Sep 9.
Abstract

Oral combination therapy: Future hepatitis C virus treatment?
Hézode C.
J Hepatol. 2011 May
Abstract

Current drug discovery strategies for treatment of hepatitis C virus infection.
Cheng KC, Gupta S, Wang H,  et al
J Pharm Pharmacol. 2011 Jul;63(7):883-92.
Abstract

Antiviral therapy: why does it fail in HCV-related chronic hepatitis?
Masarone M, Persico M.
Expert Rev Anti Infect Ther. 2011 May;9(5):535-43..
Abstract

Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection:
a cure and so much more.
Pearlman BL, Traub N.
Clin Infect Dis. 2011 Apr;52(7):889-900
Abstract

Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects?
Gluhovschi C, Gadalean F, Kaycsa A, et al
Immunopharmacol Immunotoxicol. 2011 Feb 14
Abstract

Hepatitis C virus Resistance to Protease Inhibitors.
Halfon P, Locarnini S.
J Hepatol
. 2011 Jan 29.
Abstract

Mixing the right hepatitis C inhibitor cocktail.
Gelman MA, Glenn JS.
Trends Mol Med
. 2010 Nov 22.
Abstract

Susceptibility of Treatment-Naive HCV Clinical Isolates to HCV Protease Inhibitors.
Bae A, Sun SC, Qi X, et al
Antimicrob Agents Chemother
. 2010 Sep 20
Abstract

Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy:
a double-blind, placebo-controlled trial.
Morasco BJ, Loftis JM, Indest DW,
 et  al
Psychosomatics
. 2010 Sep;51(5):401-8.
Abstract

Viral response to specifically targeted antiviral therapy for hepatitis C
and the implications for treatment success.
Cooper C.
Can J Gastroenterol. 2010 Jun;24(6):385-90
Abstract

New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals.
Seden K, Back D, Khoo S.
J Antimicrob Chemother
. 2010 Mar 23
Abstract

Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C
virus-related cirrhosis.
Singal AK, Singh A, Jaganmohan  et al 
Clin Gastroenterol Hepatol. 2009 Oct 29
Abstract

Compound Chinese herbal medicines, Chinese herbal drugs and their active extracts for treatment
of chronic hepatitis C: a systematic review and meta-analysis of randomized clinical trials

Qin XK, Han M, Liu JP.
Zhong Xi Yi Jie He Xue Bao. 2009 Oct;7(10):913-28.
Abstract

Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C.
Sroczynski G, Esteban E, Conrads-Frank A,, et a;
J Viral Hepat
. 2009 Jul 28.
Abstract

New and experimental therapies for HCV.
Pereira AA, Jacobson IM.
Nat Rev Gastroenterol Hepatol
. 2009 Jul;6(7):403-11.
Abstract

Decline in Male Sexual Desire, Function, and Satisfaction During and
After Antiviral Therapy for Chronic Hepatitis C.
Dove LM, Rosen RC, Ramcharran D, et al
Gastroenterology
. 2009 Jun 12.
Abstract

Antiviral resistance and specifically targeted therapy for HCV (STAT-C).
Thompson AJ, McHutchison JG.
 J Viral Hepat. 2009 Jun;16(6):377-87
Abstract

New drug targets for hepatitis C and other flaviviridae viruses.
Paula T, Pablo R, Eugenia V, et al
Infect Disord Drug Targets. 2009 Mar;9(2)
Abstract
 

Hepatitis C virus drug resistance and immune-driven adaptations: Relevance to new antiviral therapy.
Gaudieri S, Rauch A, Pfafferott K, et al
Hepatology
. 2008 Dec 8

Abstract
 
Antiviral therapy for recurrent liver graft infection with hepatitis C virus.
Gurusamy KS, Osmani B, Xirouchakis E, et al
Cochrane Database Syst Rev
. 2009 Jan 21;(1):CD006803.
Abstract
 
New data and recommendations of antiviral therapy of chronic hepatitis B and C.
Niederau C.
Internist (Berl). 2008 Mar 15
Abstract
 
Treatment regimens for patients with chronic hepatitis C.
Trapero-Marugan M, González-Moreno L, Chaparro-Sánchez M, et al
Minerva Gastroenterol Dietol.
2008 Jun;54(2):209-17.
Abstract
 
Antiviral therapy for chronic hepatitis C in patients with inherited bleeding disorders:
an international, multicenter cohort study.

Posthouwer D, Yee TT, Makris M, et al
J Thromb Haemost. 2007 Aug;5(8):1624-1629.
Abstract
 
Glucose Abnormalities Are an Independent Risk Factor for Nonresponse to Antiviral Treatment in
Chronic Hepatitis C.

Lecube A, Hernández C, Simó R, et al
Am J Gastroenterol. 2007 Jul 7;
Abstract
 
Viral determinants of resistance to treatment in patients with hepatitis C
Wohnsland A, Hofmann WP, Sarrazin C.   
Clin Microbiol Rev.
2007 Jan;20(1):23-38.
Abstract
 
Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic.
Mehta SH, Lucas GM, Mirel LB, et al
AIDS.
2006 Nov 28;20(18):2361-9.
Abstract
 
Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis:
A long-term follow-up study.
Saadoun D, Resche-Rigon M, et al 
Arthritis Rheum.
2006 Oct 30;54(11):3696-3706
Abstract
 
Antiviral treatment of hepatitis C.
Toniutto P, Fabris C, Pirisi M.
Expert Opin Pharmacother.
2006 Oct;7(15):2025-35.
Abstract
 
Effectiveness of Antiviral Therapy in Patients with Chronic Hepatitis C Treated by Private
Practice Gastroenterologists.
Hofmann WP, Bock H, Weber C, et al
Z Gastroenterol. 2006 Jan;44(1):25-31.
Abstract

The impact of antiviral treatments on the course of chronic hepatitis C: an evidence-based
approach.
Camma C, Di Bona D, Craxi A. 
Curr Pharm Des. 2004;10(17):2123-30.
Abstract
 

    Conference Reports, Abstracts, and Posters
 
 
HCV Resistance: Implications for Drug Development in the Coming Interferon-free World
D Wyles
(19 CROI)
Abstract
 
Polymorphisms at Resistance-associated Positions in HCV NS3 Protease Confer Subtle Reductions in NS3/4A Inhibitor Susceptibility
J Toma, A Newton, A Frantzell, et al
(19 CROI)
Abstract
 
Natural Variation in HCV Genotype 1 NS5A Sequences and Susceptibility to NS5A Inhibitors
J Cook , A Newton, A Frantzell,  et al
(19 CROI)
Abstract

POSTER
Using the Substrate Envelope to Avoid Drug Resistance against HCV NS3/4A Protease Inhibitors
K Romano, A Ali, W Royer, C Schiffer
(18 CROI)
PDF Poster     Abstract

New Antiviral Therapies in the Management of HCV
S Zeuzem
(18 CROI)
Abstract

POSTER
Influence of HAART on Hepatitis C Virus Escape from CD8+ T Cell Immune Pressure
J Rohrbach, M Tschochner, A Chopra, et al
(17 CROI)
PDF Poster
     Abstract

The effect of nucleoside free HAART on the treatment of chronic HCV infection
M. Vogel, G. Ahlenstiel, G. Klausen, et al
(5IAS Conference)
Abstract


Asunapravir
 

     Journal Papers, Abstracts, and Commentaries

  Single and Multiple Ascending Dose Studies of the NS3 Protease Inhibitor, Asunaprevir,
in Subjects With or Without Chronic Hepatitis C.
Pasquinelli C, McPhee F, Eley T, et al
Antimicrob Agents Chemother. 2012 Jan 30.
Abstract

Boceprevir
 

     Journal Papers, Abstracts, and Commentaries

 
A Multiplex LC-MS/MS Assay for the Simultaneous Therapeutic Drug Monitoring of Ribavirin, Boceprevir and Telaprevir.
Aouri M, Moradpour D, Cavassini M, et al
Antimicrob Agents Chemother
. 2013 Apr 29.
Abstract

FULL-TEXT PDF ARTICLE
Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study
Ferrante SA, Chhatwal J, Brass CA,  et al
BMC Infect Dis
. 2013 Apr 27;13(1):190
Paper

A WEEK-IN-REVIEW FEATURED REPORT
A Small Percentage of Patients with Hepatitis C Receive Triple Therapy with Boceprevir or Telaprevir.
Chen EY, Sclair SN, Czul F, et al
Clin Gastroenterol Hepatol. 2013 Apr 16.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Pharmacokinetic Evaluation of the Interaction Between the HCV Protease Inhibitor Boceprevir and the HMG-CoA Reductase Inhibitors Atorvastatin and Pravastatin.
Hulskotte E, Feng HP, Xuan F, et al
Antimicrob Agents Chemother. 2013 Mar
Abstract

Boceprevir-based tritherapy of HCV-infected Belgian liver-transplanted patients: Preliminary experience.
Degré D, Colle I, Van Vlierberghe H, Moreno C.
Liver Transpl. 2013 Mar 14.
Abstract

A WEEK-IN REVIEW FEATURED REPORT
Telaprevir Versus Boceprevir in Chronic Hepatitis C: A Meta-Analysis of Data From Phase II and III Trials.
Sitole M, Silva M, Spooner L,  et al
Clin Ther. 2013 Jan 29
Abstract

Optimal treatment with boceprevir for chronic HCV infection.
Maasoumy B, Manns MP.
Liver Int. 2013 Feb;33 Suppl 1:14-22.
Abstract

Serious neuropsychiatric adverse effects in a hepatitis C virus/hepatitis B virus/HIV-coinfected patient receiving bosentan and telaprevir.
Lê MP, Gervais A, Le Beller C, et al
J Antimicrob Chemother. 2013 Jan 20.
.
Abstract

In Vitro Assessment of Drug-drug Interaction Potential of Boceprevir Associated with Drug Metabolizing Enzymes and Transporters.
Chu X, Cai X, Cui D,  et al
Drug Metab Dispos. 2013 Jan 4.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Pharmacokinetic Interactions Between the Hepatitis C Virus Protease Inhibitor Boceprevir and Ritonavir-Boosted HIV-1 Protease Inhibitors Atazanavir, Darunavir, and Lopinavir.
Hulskotte EG, Feng HP, Xuan F, et al
Clin Infect Dis. 2012 Dec 14.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Boceprevir: a review of its use in the management of chronic hepatitis C genotype 1 infection.
Garnock-Jones KP.
Drugs. 2012 Dec 24;72(18):2431-56.

Abstract

Boceprevir: A recently approved protease inhibitor for hepatitis C virus infection.
Lam JT, Jacob S.
Am J Health Syst Pharm. 2012 Dec 15;69(24):2135-9.

Abstract

Boceprevir in combination with HIV protease inhibitors in patients with advanced fibrosis-altered drug-drug interactions?
Schwarze-Zander C, Boesecke C,  et al
J Int AIDS Soc. 2012 Nov 11;15(6):18418.
Abstract

Boceprevir and personalized medicine in hepatitis C virus infection.
Habersetzer F, Leboeuf C, Doffoël M, Baumert TF.
Pharmgenomics Pers Med. 2012;5:125-37

Abstract

Stereoselective Addition of 2-phenyloxazol-4-yl trifluoromethanesulfonate to N-Sulfinyl Imines: Application to the Synthesis of the HCV Protease Inhibitor Boceprevir.
Morris WJ, Muppalla KK, Cowden C, Ball RG.
J Org Chem. 2012 Dec 6

Abstract

The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir.
Marks KM, Jacobson IM.
Antivir Ther
. 2012;17(6 Pt B):1119-31.
Abstract

A WEEK-IN REVIEW FEATURED REPORT
Pharmacokinetic Interactions Between the HCV Protease Inhibitor Boceprevir and Ritonavir-Boosted HIV-1 Protease Inhibitors Atazanavir, Darunavir, and Lopinavir.
Hulskotte EG, Feng HP, Xuan F, et al
Clin Infect Dis. 2012 Nov 15.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT 
The Relative Efficacy of Boceprevir and Telaprevir in the Treatment of HCV Genotype 1.
Schmitz S, O'Leary A, Walsh C, Bergin C, Norris S.
Clin Infect Dis. 2012 Oct 16.
Abstract

Pharmacokinetic Interaction between Boceprevir and Etravirine in HIV/HCV Seronegative Volunteers.
Hammond KP, Wolfe P, Burton JR Jr, :

J Acquir Immune Defic Syndr
. 2012 Oct 15
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Boceprevir: A Protease Inhibitor for the Treatment of Hepatitis C.
Chang MH, Gordon LA, Fung HB.
Clin Ther. 2012 Sep 10.
Abstract

Practical Management of Boceprevir and Immunosuppressive Therapy in Liver Transplant Recipient Recurrence
Coilly A, Furlan V, Roche B,  et al
Antimicrob Agents Chemother.2012 Aug 29
Abstract

Triple therapy with boceprevir or telaprevir for treatment naïve HCV patients.
Esteban R, Buti M.
Best Pract Res Clin Gastroenterol.
Abstract

Triple therapy with boceprevir or telaprevir for prior HCV non-responders.
Asselah T.
Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):455-62
Abstract

The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir.
Marks KM, Jacobson IM.
Antivir Ther. 2012;17(6 Pt B):1119-31.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT

Factors that Predict Response of Patients with HCV Infection to Boceprevir.
Poordad F, Bronowicki JP, Gordon SC,  et al

Gastroenterology. 2012 May 21
Abstract

Review of boceprevir and telaprevir for the treatment of chronic hepatitis C.
Wilby KJ, Partovi N, Ford JA, Greanya E, Yoshida EM.

Can J Gastroenterol
. 2012 Apr;26(4):205-10.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection.
Trembling PM, Tanwar S, Dusheiko GM.
Expert Rev Anti Infect Ther
. 2012 Mar;10(3):269-79.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients.
Wilby KJ, Greanya ED, Ford JA,, et al

Ann Hepatol
. 2012 Mar;11(2):179-85.
Abstract

Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C.
Sarrazin C, Berg T, Cornberg M,  et al
Z Gastroenterol. 2012 Jan;50(1):57-72.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?
Shiffman ML, Esteban R.
Liver Int. 2012 Feb;32 Suppl 1:54-60.
Abstract

Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1
Manns MP, Markova AA, Serrano BC, Cornberg M.
Liver Int. 2012 Feb;32 Suppl 1:27-31.
Abstract

Specific Detection of Naturally Occurring Telaprevir and Boceprevir (Protease Inhibitors)
HCV Resistant Mutants among Treatment Naive Infected Individuals.
Fonseca-Coronado S, Escobar-Gutiérrez A, Ruiz-Tovar K, et al
J Clin Microbiol. 2011 Nov 23.
Abstract

Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus.
Tungol A, Rademacher K, Schafer JA.
J Manag Care Pharm. 2011 Nov;17(9):685-94.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease
after treatment with telaprevir or boceprevir.
Susser S, Vermehren J, Forestier N, et al
J Clin Virol. 2011 Sep 14.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Boceprevir: A Protease Inhibitor for the Treatment of Chronic Hepatitis C (September).
Foote BC, Spooner LM, Belliveau PP.
Ann Pharmacother. 2011 Aug 9
Abstract

A sprint to increase response to HCV treatment: expectancies but caution.
Asselah T.

J Hepatol
. 2011 Jun 30
Abstract

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b
and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1):
an open-label, randomised, multicentre phase 2 trial.

Kwo PY, Lawitz EJ, McCone J,. et al
Lancet. 2010 Aug 28;376(9742):705-16
Abstract

Highly sensitive determination of HCV protease inhibitors boceprevir (SCH 503034) and
telaprevir (VX 950) in human plasma by LC-MS/MS.
Farnik H, El-Duweik J, Welsch C,
J Chromatogr B Analyt Technol Biomed Life Sci
. 2009 Dec 1;877(31):4001
Abstract

    Conference Reports, Abstracts, and Posters

 
Absence of a Significant Pharmacokinetic Interaction between the Hepatitis C Virus Protease Inhibitor Boceprevir and HIV-1 NNRTI Rilpivirine
Elizabeth Rhee, H-P Feng, F Xuan, et al
(20 CROI)
Abstract

POSTER
The Influence of the HCV Protease Inhibitor Boceprevir on the Pharmacokinetics of the HIV Integrase I
nhibitor Raltegravir

C de Kanter, M Blonk, A Colbers, et al
(19 CROI)
PDF Poster
     Abstract

 

POSTER
Pharmacokinetic Interaction between the HCV Protease Inhibitor Boceprevir and Ritonavir-boosted HIV-1
 Protease Inhibitors Atazanavir, Lopinavir, and Darunavir

E Hulskotte, H-P Feng, F Xuan,  et al
(19 CROI)
PDF Poster
     Abstract

 
POSTER
Frequencies of Resistance-associated Amino Acid Variants following Combination
Treatment with BOC + P/R in Patients with Chronic HCV, Genotype-1

R Barnard L Pedicone, E Chaudhri,  et al
(18 CROI)
PDF Poster     Abstract

HCV RESPOND-2 Final Results: High Sustained Virologic Response among Genotype-1
Previous Non-responders and Relapsers to pegIFN/RBV when Re-treated with BOC +
PEGINTRON/RBV

S Gordon,  B Bacon, E Lawitz,  et al
(18 CROI)
Abstract

BOC Combined with P/R for Treatment-naïve Patients with HCV Genotype-1: SPRINT-2 Final Results
M Sulkowski, F Poordad, J McCone, et al
18 CROI)
Abstract


Corticosteroids
 

     Journal Papers, Abstracts, and Commentaries

  Differential efficacy of corticosteroids and interferon in a patient with chronic hepatitis
C-autoimmune hepatitis overlap syndrome.
Petersen-Benz C, Kasper HU, Dries V, Goeser T.
Clin Gastroenterol Hepatol. 2004 May;2(5):440-3
Abstract

Cyclosporine
 

   Journal Papers, Abstracts, and Commentaries
 
  FULL-TEXT ARTICLE
Cyclosporine versus tacrolimus in patients with HCV infection after liver transplantation:
Effects on virus replication and recurrent hepatitis.
Hilgard P, Kahraman A, Lehmann N, et al 
World J Gastroenterol. 2006 Feb 7;12(5):697-702.

Paper

Erythropoietin
 

     Journal Papers, Abstracts, and Commentaries
 
 

Clinical recommendations for the use of recombinant human erythropoietin in patients with
hepatitis C virus being treated with ribavirin.

Sherman M, Cohen L, Cooper MA, et al 
Can J Gastroenterol.
2006 Jul;20(7):479-85.

Abstract

Epoetin alfa for the Treatment of Combination Therapy-Induced Hemolytic Anemia in
Patients Infected with Hepatitis C Virus.
Rivkin AM, Chawla S. 
Pharmacotherapy. 2005 Jun;25(6):862-7
Abstract 

Normal erythropoietin response in chronic hepatitis C patients with ribavirin-induced anaemia.
Durante Mangoni E, Marrone A, Saviano D
Antivir Ther. 2003 Feb;8(1):57-63
Abstract

Etanercept
 

     Journal Papers, Abstracts, and Commentaries

  Treatment with etanercept in six patients with chronic hepatitis C infection
and systemic autoimmune diseases.

Cavazzana I, Ceribelli A, Cattaneo R, Franceschini F.

Autoimmun Rev. 2008 Dec;8(2):104-6.

Abstract

Gammaglobulin
 

     Journal Papers, Abstracts, and Commentaries
 
  Fibrosis regression induced by intravenous gammaglobulin treatment.
Amital H, Rewald E, Levy Y, et al.
Ann Rheum Dis
2003 Feb;62(2):175-177

Abstract

Immunoglobulin
 

      Journal Papers, Abstracts, and Commentaries
 
  Prophylaxis of Hepatitis C with Intramuscular Immunoglobulin: Clinical and Economic Appraisal.
Piazza M, Sagliocca L, Tosone G, et al
BioDrugs. 1999 Oct;12(4):291-300.
Abstract

Lopinavir
 

    Conference Reports, Abstracts, and Posters
 
  POSTER
HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV coinfected patients starting anti-HCV treatment:
final results of a randomised, proof-of- principle clinical trial (KAMON 2 Study)

H. Hasson, L. Galli, G. Gallotta
(6th IAS Conference)

Poster      Abstract

Meloxicam
 

     Journal Papers, Abstracts, and Commentaries
 
  Eight-week oral administration of meloxicam, a non-steroidal anti-inflammatory drug, prevents
dose reduction of pegylated interferon alpha-2a in the treatment of chronic hepatitis C.

Kagawa T, Shiozawa H, Kojima SI, et al 
Hepatol Res.
2007 Sep 6;

Abstract

Metformin
 

     Journal Papers, Abstracts, and Commentaries
 
  Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients
receiving peginterferon alfa-2a plus ribavirin.
Romero-Gómez M, Diago M, Andrade RJ, et al 
Hepatology. 2009 Dec;50(6):1702-8.
Abstract

Nevirapine
 

     Journal Papers, Abstracts, and Commentaries
 
  Analysis of Severe Hepatic Events Associated with Nevirapine-Containing Regimens :
CD4+ T-Cell Count and Gender in Hepatitis C Seropositive and Seronegative Patients.
Torti C, Costarelli S, De Silvestri A, et al 
Drug Saf.
2007;30(12):1161-9.

Abstract

Raltegravir
 

     Journal Papers, Abstracts, and Commentaries
 
  Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C.
Vispo E, Mena A, Maida I, et al
J Antimicrob Chemother
. 2009 Dec 23

Abstract

Rifampin
 

Rifampin/Pyrazinamide

     Journal Papers, Abstracts, and Commentaries

  Severe hepatotoxicity associated with rifampin-pyrazinamide preventative therapy
requiring transplantation in an individual at low risk for hepatotoxicity.
Kunimoto D, Warman A, Beckon A,  et al.
Clin Infect Dis. 2003 Jun 15;36(12):E158-61

Abstract

Rituximab
 

   Journal Papers, Abstracts, and Commentaries
 
 
FULL-TEXT ARTICLE
Efficacy and safety of rituximab in the treatment of vasculitic leg ulcers associated with hepatitis C virus infection.
Bonilla-Abadía F, Echeverri AF,  et al
Case Report Rheumatol. 2012;2012:923897.
Paper

FULL-TEXT ARTICLE
Rituximab treatment in hepatitis C infection: an in vitro model to study the impact of B cell depletion
on virus infectivity.

Stamataki Z, Tilakaratne S, Adams DH, McKeating JA.

PLoS One
. 2011;6(9):e25789.
Paper

Rituximab plus Peg-Interferon {alpha} /ribavirin compared to Peg- Interferon
{alpha} /ribavirin in Hepatitis C related mixed cryoglobulinemia.
Saadoun D, Resche Rigon M, et al
Blood
. 2010 May
Abstract

Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b
plus ribavirin in severe hepatitis C virus-related vasculitis: A long-term followup
study of thirty-two patients.
Terrier B, Saadoun D, Sène D, et al
Arthritis Rheum
. 2009 Jul 30;60(8):2531-2540.
Abstract

Hepatitis C virus infection and rituximab therapy after renal transplantation.
Fabrizi F, Martin P, Elli A, et al 
Int J Artif Organs.
2007 May;30(5):445-9.

Abstract


Statins
 

   Journal Papers, Abstracts, and Commentaries
 
  Statin Therapy and Serum Transaminases Among a Cohort of HCV-Infected Veterans.
Henderson LM, Patel S, Giordano TP, et al 
Dig Dis Sci
. 2009 Sep 3.
Abstract

Stribild
 

    Conference Reports, Abstracts, and Posters
 
  Acute Hepatitis C Virus Infection in Studies of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (Stribild) and Cobicistat for Initial HIV-1 Therapy
Erin Quirk, H Graham, H Liu, J Szwarcberg
(20th CROI)
Abstract
 

Telaprevir
 

  News
 
 

FDA Approves Telaprevir for HCV
USFDA

May 23, 2011
News Release

   Journal Papers, Abstracts, and Commentaries

 
A WEEK-IN-REVIEW FEATURED REPORT
Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir.
Benito JM, Sánchez-Parra C, et al
Antivir Ther
. 2013 May 3. |
Abstract

A Multiplex LC-MS/MS Assay for the Simultaneous Therapeutic Drug Monitoring of Ribavirin, Boceprevir and Telaprevir.
Aouri M, Moradpour D, Cavassini M, et al
Antimicrob Agents Chemother
. 2013 Apr 29.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
A Small Percentage of Patients with Hepatitis C Receive Triple Therapy with Boceprevir or Telaprevir.
Chen EY, Sclair SN, Czul F, et al
Clin Gastroenterol Hepatol. 2013 Apr 16.
Abstract

Telaprevir: Changing the standard of care of chronic hepatitis C.
Rajani AK, Ravindra BK, Dkhar SA.
J Postgrad Med
. 2013 Jan-Mar;59(1):42-7
Abstract

A WEEK-IN REVIEW FEATURED REPORT
Telaprevir Versus Boceprevir in Chronic Hepatitis C: A Meta-Analysis of Data From Phase II and III Trials.
Clin Ther. 2013 Jan 29
Abstract

A WEEK-IN REVIEW FEATURED REPORT
Review of drug interactions with telaprevir and antiretrovirals.
van Heeswijk RP, Beumont M, Kauffman RS, Garg V.
Antivir Ther
. 2013 Jan 23.
Abstract

Serious neuropsychiatric adverse effects in a hepatitis C virus/hepatitis B virus/HIV-coinfected patient receiving bosentan and telaprevir.
Lê MP, Gervais A, Le Beller C, et al
J Antimicrob Chemother. 2013 Jan 20.

Abstract

A WEEK-IN REVIEW FEATURED REPORT
Optimal treatment with telaprevir for chronic HCV infection.
Jesudian AB, Jacobson IM.
Liver Int. 2013 Feb;33 Suppl 1:3-13
Abstract

A WEEK-IN REVIEW FEATURED REPORT
FULL-TEXT ARTICLE

Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis.
Kong Y, Wang X, Shang Y, , et al
PLoS One
. 2012;7(12):e52158.
Paper

Telaprevir-based triple-therapy in patients with chronic hepatitis C in Germany: a 12-week interim analysis of real-life data.
Berg T, Buggisch P, Hueppe D,  et al
J Int AIDS Soc. 2012 Nov 11;15(6):18424.
Abstract

Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon-alpha-2b and ribavirin in hepatitis C patients.
Suzuki F, Suzuki Y, Sezaki H, et al
Hepatol Res. 2012 Nov 29.
Abstract

A WEEK-IN REVIEW FEATURED REPORT

The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir.
Marks KM, Jacobson IM.
Antivir Ther
. 2012;17(6 Pt B):1119-31.
Abstract

Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: Is it feasible?
Dumortier J, Guillaud O, Gagnieu MC, et al
J Clin Virol
. 2012 Nov 10.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT 
The Relative Efficacy of Boceprevir and Telaprevir in the Treatment of HCV Genotype 1.
Schmitz S, O'Leary A, Walsh C, Bergin C, Norris S.
Clin Infect Dis. 2012 Oct 16.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Short report: Telaprevir-based triple therapy in liver transplanted HCV patients: A 12 week pilot study
providing safety and efficacy.
Werner CR, Egetemeyr DP, Lauer UM, et al

Liver Transpl
. 2012 Sep 1.
Abstract

Triple therapy with boceprevir or telaprevir for treatment naïve HCV patients.
Esteban R, Buti M.
Best Pract Res Clin Gastroenterol.

Abstract

Triple therapy with boceprevir or telaprevir for prior HCV non-responders.
Asselah T.
Best Pract Res Clin Gastroenterol
. 2012 Aug;26(4):455-62
Abstract

The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir.
Marks KM, Jacobson IM.
Antivir Ther
. 2012;17(6 Pt B):1119-31.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Safety of Telaprevir for Chronic Hepatitis C Virus Infection: A Meta-Analysis of Randomized Controlled Trials.
Qin H, Li H, Zhou X,  et al
Clin Drug Investig. 2012 Aug 14.

Abstract

Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with
HCV genotype 1.
Akuta N, Suzuki F, Seko Y,  et al

J Med Virol
. 2012 Jul;84(7):1097-105.
Abstract

Review of boceprevir and telaprevir for the treatment of chronic hepatitis C.
Wilby KJ, Partovi N, Ford JA, Greanya E, Yoshida EM.
Can J Gastroenterol. 2012 Apr;26(4):205-10.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C.
Perry CM.

Drugs
. 2012 Mar 26;72(5):619-41.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Efficacy and safety of telaprevir in patients with genotype 1 hepatitis C infection.
Cunningham M, Foster GR.

Therap Adv Gastroenterol
. 2012 Mar;5(2):139-51.
Abstract

A WEEK-IN REVIEW FEATURED REPORT
A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients.
Wilby KJ, Greanya ED, Ford JA,, et al
Ann Hepatol
. 2012 Mar;11(2):179-85.
Abstract

Telaprevir for the treatment of hepatitis C.
Forestier N, Zeuzem S.
Expert Opin Pharmacother
. 2012 Feb 15
Abstract

Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C.
Sarrazin C, Berg T, Cornberg M,  et al
Z Gastroenterol
. 2012 Jan;50(1):57-72.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?
Shiffman ML, Esteban R.
Liver Int
. 2012 Feb;32 Suppl 1:54-60.
Abstract

Telaprevir user's guide.
Liapakis AM, Jacobson I.
Liver Int. 2012 Feb;32 Suppl 1:17-25
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Telaprevir for the treatment of chronic hepatitis C infection.
Muir AJ.
Expert Rev Anti Infect Ther
. 2011 Dec;9(12):1105-14.
Abstract

Specific Detection of Naturally Occurring Telaprevir and Boceprevir (Protease Inhibitors)
HCV Resistant Mutants among Treatment Naive Infected Individuals.
Fonseca-Coronado S, Escobar-Gutiérrez A, Ruiz-Tovar K, et al
J Clin Microbiol
. 2011 Nov 23.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus
Kwong AD, Kauffman RS, Hurter P, Mueller P.
Nat Biotechnol
. 2011 Nov 8;29(11):993-1003.
Abstract

The Pharmacokinetic Interaction Between an Oral Contraceptive Containing Ethinyl Estradiol
and Norethindrone and the HCV Protease Inhibitor Telaprevir.
Garg V, van Heeswijk R, Yang Y,  et al
J Clin Pharmacol. 2011 Oct 30.

Abstract

Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus.
Tungol A, Rademacher K, Schafer JA.
J Manag Care Pharm
. 2011 Nov;17(9):685-94.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior
treatment response.
Muir AJ, Poordad FF, McHutchison JG, et al
H epatology
. 2011 Nov;54(5):1538-46.
Abstract

Telaprevir for Chronic Hepatitis C with Genotype 1: A Meta-Analysis.
Dang SS, Wang WJ, Wang XF,
Hepatogastroenterology
. 2011 Aug 10;59(114).
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease
after treatment with telaprevir or boceprevir.
Susser S, Vermehren J, Forestier N, et al
J Clin Virol
. 2011 Sep 14.

Abstract

Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with
HCV of genotype 1 in Japan.

K
umada H, Toyota J, Okanoue T,  et al
J Hepatol. 2011 Aug 6
Abstract

Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir
 (VX-950) and danoprevir (ITMN-191).
Imhof I, Simmonds P.
Hepatology
. 2011 Apr;53(4):1090-9
Abstract

Second phase HCV RNA decline during telaprevir based therapy increases with drug effectiveness:
Implications for treatment duration.
Guedj J, Perelson AS.
Hepatology. 2011 Mar 7.
Abstract

The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus.
Gentile I, Carleo MA, Borgia F, et al
Expert Opin Investig Drugs
. 2010 Jan;19(1):151-9.
Abstract
 
Characterization of resistance to the protease inhibitor boceprevir in hepatitis C
virus-infected patients.
Susser S, Welsch C, Wang Y, et al
Hepatology
. 2009 Dec;50(6):1709-18.
Abstract

Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment
with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks.
Suzuki F, Akuta N, Suzuki Y, et al
Hepatol Res
. 2009 Nov;39(11):1056-63
Abstract
 
Sustained virological response in a patient with chronic hepatitis C treated by monotherapy
with the NS3-4A protease inhibitor telaprevir.
Suzuki F, Suzuki Y, Akuta N,
et al
Clin Virol
. 2009 Oct 24.
Abstract

Telaprevir: hope on the horizon, getting closer.
Weisberg IS, Jacobson IM.
Clin Liver Dis
. 2009 Aug;13(3):441-52
Abstract
 
FULL-TEXT ARTICLE
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
Hézode C, Forestier N, Dusheiko G, et al
N Engl J Med
. 2009 Apr 30;360(18):1839-50
Paper

Telaprevir for previously treated chronic HCV infection.
McHutchison JG, Manns MP, Muir AJ, et al
N Engl J Med
. 2010 Apr 8;362(14):1292-30
3.
Abstract

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
Hézode C, Forestier N, Dusheiko G, et al
N Engl J Med
. 2009 Apr 30;360(18):1839-50
Abstract

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.
McHutchison JG, Everson GT, Gordon SC, et al
N Engl J Med
. 2009 Apr 30;360(18):1827-38
Abstract
 
Telaprevir: a promising protease inhibitor for the treatment of hepatitis C virus infection.
Gentile I, Viola C, Borgia F, Castaldo G, Borgia G.
Curr Med Chem. 2009;16(9):1115-21.

AbstractT

 
    Conference Reports, Abstracts, and Posters
 
 
POSTER
Telaprevir, Pegylated Interferon, and Ribavirin Combination Therapy for Chronic Hepatitis C Virus Genotype 1 in Hepatitis C Virus/HIV Co-infected Patients: Early Response and Viral Resistance
Kenneth Sherman, D Bartels M Bsharat, et al

(20th CROI)
PDF Poster     Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Triple Combination Therapy for Hepatitis C with Telaprevir Exhibits Higher Early Antiviral Potency than with Boceprevir Regardless HIV Status
Jose Miguel Benito, K Bichoupan, V Soriano, et al
(20th CROI)
Abstract

Telaprevir Combination Treatment in Hard-to-treat African American, Null Responder G1 Chronic Hepatitis C Patients: Early Data from the OUTLOOK Study
Steven Flamm, E Martin A Muir, et al

(20th CROI)
Abstract

POSTER
Low-dose RTV and the Pharmacokinetics of the Investigational HCV Protease Inhibitor TVR in Healthy
Volunteers

V  Gar, X Luo, L McNair, et al
(18 CROI)

PDF Poster     Abstract

Pharmacokinetic Interactions between ARV Agents and the Investigational HCV Protease Inhibitor TVR in
Healthy Volunteers

R van Heeswijk, A Vandevoorde, G Boogaerts, et al
V  Gar, X Luo, L McNair, et al
(18 CROI)
Abstract


Thalidomide
 

   Journal Papers, Abstracts, and Commentaries
 
  Thalidomide in the treatment of chronic hepatitis C unresponsive to alfa-interferon and
ribavirin.
Milazzo L, Biasin M, Gatti N, et l
Am J Gastroenterol. 2006 Feb;101(2):399-402

Abstract

Valproic Acid
 

     Journal Papers, Abstracts, and Commentaries
 
  The safety of valproic Acid use for patients with hepatitis C infection.
Felker BL, Sloan KL, Dominitz JA, Barnes RF.
Am J Psychiatry
2003 Jan;160(1):174-8

Abstract

Alternate Therapies
 

     Journal Papers, Abstracts, and Commentaries

 
High-dose silibinin rescue treatment for HCV-infected patients showing suboptimal virologic response to
standard combination therapy.
Biermer M, Schlosser B, Fülöp B, et al

J Viral Hepat
. 2012 Aug;19(8):547-53
Abstract

High prevalence of potentially hepatotoxic herbal supplement use in patients with
fulminant hepatic failure

Estes JD, Stolpman D, Olyaei A 

Arch Surg.
2003 Aug;138(8):852-8.
Abstract

The use of alternative medicine in the treatment of hepatitis C.
Bean P
Am Clin Lab 2002 May;21(4):19-21
Abstract

 

HCV Main Page Main New/Newsworthy    Home Page    

HCV Drugs

.